{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"40.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"18"}],"units":"Participants"}],"description":"To determine the recommended dose (RD) of plitidepsin in combination with bortezomib and dexamethasone in patients with relapsed and/or refractory multiple myeloma (MM). To define the RD, patients will be evaluated for DLTs during the first 28-day cycle. The RD will be the highest DL at which fewer than two out of six (33%) of evaluable patients experience a DLT during the first 28-day cycle.","groups":[{"description":"All participants who received at least 1 dose of plitidepsin as a 3-hour i.v. infusion on Days 1 and 15 in combination with BTZ administered s.c. on Days 1, 4, 8 and 11, and DXM orally on Days 1, 8, 15 and 22 q4wk in patients with relapsed and/or refractory MM","id":"OG000","title":"All Participants"}],"paramType":"NUMBER","populationDescription":"Participants who received at least 1 dose study treatment","reportingStatus":"POSTED","timeFrame":"After 28-day cycle","title":"Recommended Dose of Dexamethasone in Combination With Plitidepsin and Bortezomib","type":"PRIMARY","unitOfMeasure":"mg of dexamethasone"}